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OBJECTIVE—The implication of innate immunity in type 1
diabetes development has long been proposed. High-mobility
group box 1 (HMGB1), an evolutionarily conserved chromo-
somal protein, was recently recognized to be a potent innate
inﬂammatory mediator when released extracellularly. We sought
to test the hypothesis that HMGB1 acts as an innate immune
mediator implicated in type 1 diabetes pathogenesis.
RESEARCH DESIGN AND METHODS—Eight- and 12-week-
old NOD mice were treated with an HMGB1 neutralizing anti-
body once a week until 25 weeks of age and monitored for
insulitis progression and diabetes onset. The underlying mecha-
nisms of HMGB1 regulation of autoimmune response were
further explored.
RESULTS—During autoimmunity, HMGB1 can be passively
released from damaged pancreatic -cells and actively secreted
by islet inﬁltrated immune cells. Extracellular HMGB1 is potent
in inducing NOD dendritic cell maturation and stimulating mac-
rophage activation. Blockade of HMGB1 signiﬁcantly inhibited
insulitis progression and diabetes development in both 8- and
12-week-old NOD mice. HMGB1 antibody treatment decreased
the number and maturation of pancreatic lymph node (PLN)
CD11c
CD11b
 dendritic cells, a subset of dendritic cells
probably associated with autoantigen presentation to naı ¨ve T-
cells, but increased the number for PLN CD4
Foxp3
 regulatory
T-cells. Blockade of HMGB1 also decreased splenic dendritic cell
allo-stimulatory capability associated with increased tolergenic
CD11c
CD8a
 dendritic cells. Interestingly, the number of
CD8
interferon-
 (Tc1) T-cells was increased in the PLNs and
spleen after blockade of HMGB1, which could be associated with
retarded migration of activated autoreactive T-cells into the
pancreatic islets.
CONCLUSIONS—Extracellular HMGB1 functions as a potent
innate immune mediator contributing to insulitis progression and
diabetes onset. Diabetes 57:2118–2127, 2008
T
ype 1 diabetes is an autoimmune disease char-
acterized by T-cell–mediated destruction of the
insulin-secreting -cells (1–3). It is believed that
environmental risk factors interact with genetic
factors to trigger the development of autoimmunity. Given
the importance of innate immunity in mediating adaptive
immune responses, its role in type 1 diabetes pathogenesis
has long been proposed (4–7). The link between innate
immunity and autoimmune diabetes is underscored by the
observation that lipopolysaccharide (LPS), viral infection,
or generalized activation of antigen-presenting cells
(APCs) delays or prevents the establishment of peripheral
tolerance (8–10). The re-discovery of toll-like receptors
reacting to endogenous damage-associated molecular pat-
terns provided additional evidence supporting a role for
innate immunity in type 1 diabetes pathogenesis (11–15).
Moreover, despite recent extensive studies, identiﬁcation
of which cells, receptors, and mediators associated with
innate immunity are critical in type 1 diabetes settings is
still a formidable challenge.
High-mobility group box 1 (HMGB1) is among the most
evolutionarily conserved proteins in the eukaryotic king-
dom (16). It was originally identiﬁed as a chromosomal
protein facilitating the binding of transcription factors to
their cognate DNA sequences (17). Recently, HMGB1 was
re-recognized as an innate “danger signal” (alarmin)
adopted by the innate immune system during evolution for
mediating adaptive immune responses (18–22). Extracel-
lular HMGB1 is potent to initiate immune responses by
inducing APC activation and mediating Th1 polarization.
Therefore, HMGB1 acts as a bridge that links innate and
adaptive immunity. Previously, we have demonstrated a
pivotal role for HMGB1 in the initiation and progression of
allograft rejection in a murine cardiac transplantation
model (23). In the current study, we have tested our
hypothesis that HMGB1 functions as a potent innate
immune mediator contributing to autoimmune progres-
sion during type 1 diabetes development. We have demon-
strated that HMGB1 can be either passively released from
damaged pancreatic -cells or secreted by islet inﬁltrated
autoreactive immune cells, such as dendritic cells. Block-
ade of HMGB1 in NOD mice not only prevents autoim-
mune progression but also delays diabetes onset. Our data
provide strong evidence indicating a role for HMGB1 in
autoimmune diabetes by regulation of dendritic cells, T
effector cells, and regulatory T-cells (Tregs).
RESEARCH DESIGN AND METHODS
NOD/LTJ (H-2
g7), C57BL/6J (H-2
b), and SWR/J (H-2
q) mice were purchased
from The Jackson Laboratories (Bar Harbor, ME) and housed in the speciﬁc
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Production and puriﬁcation of HMGB1 neutralizing antibodies. Recom-
binant HMGB1 (rHMGB1) was expressed and puriﬁed as reported and then
used to raise neutralizing antibodies in ﬁve rabbits (Covance, Denver, PA)
(23). The neutralizing activity for each antibody was determined by assay of
tumor necrosis factor- (TNF-) release after stimulating macrophages with
rHMGB1. Antibodies with neutralizing effect were ﬁrst afﬁnity-puriﬁed by
protein-A columns and then passed through polymyxin B beads to remove
possible contaminated endotoxin.
Western blot analysis of HMGB1 passive release and active secretion.
NIT-1 cells (3  10
6) were treated either with cytokines (10 units/ml
interleukin [IL]-1, 100 units/ml TNF-, and 100 units/ml interferon- [IFN-];
R&D Systems, Minneapolis, MN) for 72 h or with UV light (1 min) or 4 mol/l
camptothecin (Calibiochem, La Jolla, CA). NIT-1 cell apoptosis and secondary
necrosis after treatment were conﬁrmed using a TUNEL assay kit (Molecular
Probes, Carlsbad, CA). Necrosis was induced by three cycles of freeze-thaw
processes. Equal volumes of concentrated supernatants after each treatment
were analyzed by Western blots for HMGB1 passive release (23). Similarly,
primary islets were hand-picked under a dissection microscope after digestion
and then dissociated into single cells for the same assay (24). For detection of
HMGB1 active secretion, conditioned media from dendritic cells or macro-
phages were concentrated and analyzed as above.
ELISA for cytokine assay and intracellular Foxp3 or IFN- immuno-
staining. The amount of TNF- in the culture medium was determined using
a sandwich ELISA kit (eBioscience, San Diego, CA). Intracellular Foxp3 or
IFN- staining was carried out as reported (23). Flow cytometry data were
analyzed using Quest v3.3 software (BD Bioscience, San Jose, CA).
Dendritic cell preparation and mixed lymphocyte reaction assay. Bone
marrow cells were ﬂushed from femurs with RPMI 1640 supplemented with
10% FCS. Cells (5  10
5/ml) were plated in 150-mm Petri dishes supplemented
with 5 ng/ml granulocyte macrophage–colony-stimulating factor and 1 ng/ml
IL-4. Culture media were changed on days 4 and 7, stimulated with 0.5 g/ml
LPS (Sigma, St. Louis, MO) or 20 g/ml rHMGB1 for 24 h, and then harvested
on day 10 for ﬂow cytometry. Splenic dendritic cells were puriﬁed using a
mouse dendritic cell enrichment kit (StemCell, Seattle, WA). All antibodies
used for ﬂow cytometry were purchased from BD Biosciences (San Diego,
CA). NOD dendritic cell allo-stimulatory capability was determined by mixed
lymphocyte reaction as reported previously (25).
HMGB1 immunostaining. NOD bone marrow–derived dendritic cells
(BMDCs) or macrophages were ﬁxed with formaldehyde and permeabilized
with saponin. After blocking with 10% BSA, the cells were sequentially
incubated with a monoclonal HMGB1 antibody (Abnova, Taiwan) and a
ﬂuorescein isothiocyanate (FITC)-conjugated secondary antibody. Nuclei
were counterstained with propidium iodide. The cells were visualized on a
LSM510 confocal microscope (Zeiss, Oberkochen, Germany). HMGB1 immu-
nostaining in the pancreatic sections was carried out as previously described
(23).
HMGB1 neutralizing antibody treatment of pre-diabetic NOD mice.
Eight- or 12-week-old NOD female mice were used for the study. The HMGB1
neutralizing antibody (600 g/mouse) was intraperitoneally injected into each
mouse once a week starting from the indicated age until 25 weeks of age. Mice
that received the same amount of normal rabbit IgG (Sigma) that underwent
the same puriﬁcation process served as controls. For monitoring diabetes
incidence, the mice were housed in the Medical College of Georgia SPF facility
for up to 35 weeks of age. Urine glucose was checked every other day with
Diastix strips (Bayer, Elkhart, IN) when the mice reached 14 weeks of age.
Once urine glucose was detected, the mice were tested for blood glucose, and
they were diagnosed with diabetes when two consecutive blood glucose
readings were 250 mg/dl.
For monitoring insulitis, the selected mice were killed at 12, 15, and 18
weeks of age, respectively. Pancreatic sections were stained with hematoxy-
lin-eosin using the established techniques (26). Insulitis severity was scored in
a blinded fashion by two examiners using the following criteria: 0, intact islet,
no cellular inﬁltrates; 1, peri-insulitis; 2, moderate insulitis, 50% of the islet
was inﬁltrated; 3, severe insulitis, 50% of the islet was inﬁltrated. Eight mice
(200 islets) were examined at each time point for each study group.
Statistical analysis. Diabetes incidence curves were generated by the
Kaplan-Meier method. The differences of diabetes incidence between groups
were determined using the log-rank (Mantel-Cox) test. 	
2 test was used to
determine the difference for insulitis severity at each time point. Comparisons
between groups for ﬂow cytometry, cytokine production, and intracellular
cytokine expression were accomplished by one-way ANOVA using SPS 11.5
for Windows. Data are presented as means 
 SD. P  0.05 was considered
statistically signiﬁcant.
RESULTS
Puriﬁcation of rHMGB1 and production of HMGB1
neutralizing antibodies. rHMGB1 was ﬁrst puriﬁed us-
ing the Ni-NTA afﬁnity columns followed by weak cation
exchange chromatography. The puriﬁed protein was fur-
ther passed over polymyxin B columns to remove any
contaminated endotoxin. The purity of rHMGB1 was high,
as determined on SDS-PAGE (Supplemental Fig. S1A,
which is detailed in the online appendix [available at
http://dx.doi.org/10.2337/db07-1499]). Contamination of
endotoxin was 60 pg/g protein.
A proportion of the puriﬁed rHMGB1 was used to raise
antibodies in ﬁve rabbits (Covance). Antibodies produced
from each rabbit showed high speciﬁcity and titers against
HMGB1, as shown on the Western blots (Supplemental
Fig. S1B). RAW264.7 cells were then used to test the
neutralizing effect. A small scale of each antibody was
puriﬁed by protein-A columns and then passed through
polymyxin B beads to remove potential contaminated
endotoxin. rHMGB1 is potent in stimulating RAW264.7 cell
activation in a dose-dependent manner. When 20 g/ml
rHMGB1 was added into the cultures, RAW264.7 cells
secreted 18-fold higher TNF- (Fig. 1A). Next, 25 g/ml of
each puriﬁed antibody was added into the cultures 1 h
before rHMGB1 stimulation. Only one antibody showed a
strong neutralizing effect, which reduced TNF- produc-
tion by twofold (P  0.001), whereas the rest of antibodies
showed either weak or undetectable neutralizing effect,
and the control rabbit IgG failed to inhibit the stimulatory
effect, indicating the speciﬁcity of the neutralizing effect
(Fig. 1A).
rHMGB1 is potent in stimulating NOD dendritic cell
maturation. HMGB1 has been shown to be potent in
stimulating dendritic cell activation in humans, C57BL/6,
and BALB/c mice (27–29), but its effect on NOD dendritic
cells remains unexplored. To this end, we ﬁrst puriﬁed the
antibody that showed the strongest neutralizing effect. To
stimulate day-9 culture of NOD BMDCs for 24 h, 20 g/ml
rHMGB1 was used. It was found that rHMGB1 signiﬁcantly
stimulated NOD BMDC maturation, as manifested by
increased surface marker expressions shown in Fig. 1B.
To conﬁrm this observation, 25 g/ml neutralizing anti-
body was added into the cultures 1 h before rHMGB1
stimulation. As expected, addition of neutralizing antibody
signiﬁcantly inhibited rHMGB1-induced dendritic cell mat-
uration, and as a result, they showed signiﬁcantly lower
surface marker expressions than the cells with rHMGB1
treatment alone (Fig. 1B). Consistently, these dendritic
cells had signiﬁcantly less allo-stimulatory capacity than
those dendritic cells treated with rHMGB1 alone (Fig. 1C).
HMGB1 passive release from damaged pancreatic
-cells. Because HMGB1 can be passively released from
damaged cells, we sought to examine whether it can also
be released from damaged -cells. We ﬁrst checked
HMGB1 passive release in NIT-1 cells, a NOD-derived
-cell line. To induce apoptosis, 3  10
6 NIT-1 cells were
treated with combination of IL-1, TNF-, and IFN-.I n
the normal condition, NIT-1 cells showed 92% viability,
whereas 73% of the cells became apoptotic after cyto-
kine treatment, of which 79% of the apoptotic cells were
undergoing secondary necrosis (Fig. 2A). The culture
supernatants were then collected and concentrated by the
Centricon 10-kDa ﬁlter devices (Millipore, Billerica, MA).
Equal volume of each supernatant was used for Western
blot analysis of HMGB1 passive release. NIT-1 cell lysates
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positive controls (Fig. 2B, lanes 1 and 5). HMGB1 was
present in the supernatants of NIT-1 cells after cytokine
(Fig. 2B, lane 2), UV light (Fig. 2B, lane 3), and campto-
thecin (Fig. 2B, lane 4) treatment, whereas it was unde-
tectable in the control supernatant (Fig. 2B, lane 6).
Next, we pretreated NIT-1 cells with 100 mol/l Z-VAD-
FMK (Calbiochem), a broad-spectrum caspase inhibitor,
before cytokine treatment. Z-VAD-FMK signiﬁcantly pre-
vented cytokine-induced NIT-1 cell apoptosis (data not
shown) and resulted in signiﬁcantly lower HMGB1 passive
release than the cells treated with cytokine alone (Fig. 2C,
lane 3 vs. 1). We further investigated HMGB1 passive
release from apoptotic primary islet cells, and similar
results were obtained as shown in Fig. 2D.
HMGB1 active secretion by NOD autoreactive im-
mune cells. In addition to passive release, HMGB1 can
also be secreted by activated immune cells, such as
dendritic cells (28,30). To check the capacity of NOD
dendritic cells secretion of HMGB1, we ﬁrst examined
HMGB1 subcellular localization in NOD BMDCs. HMGB1
was stained with a monoclonal antibody followed by a
FITC-labeled secondary antibody. Nuclei were counter-
stained by propidium iodide. Before stimulation, HMGB1
was solely localized in the nucleus, while a large propor-
tion of HMGB1 translocated into the cytoplasm after LPS
or TNF-/IFN- stimulation, suggesting HMGB1 active
secretion (Fig. 3A). Western blot analysis of culture super-
natants conﬁrmed NOD BMDC secretion of HMGB1 in a
time-dependent manner, with the highest levels observed
after 24 h of stimulation (Fig. 3B). We further stained for
BMDCs with propidium iodide and annexin V and failed to
detect a signiﬁcant difference for cell apoptosis and sec-
ondary necrosis before/after cytokine stimulation (data
not shown). These results excluded the possibility that the
detected HMGB1 in the BMDC culture supernatants orig-
inated from damaged BMDCs. To further conﬁrm our
results, we performed similar studies in macrophages, and
consistent results were obtained (data not shown).
To explore HMGB1 active secretion by NOD islet inﬁl-
trated immune cells, we performed in situ HMGB1 immu-
nostaining using pancreatic sections originated from NOD
mice with insulitis (14 weeks old). HMGB1 (visualized by
diaminobenzidine) was exclusively localized in the nuclei
of cells in the normal islets (Fig. 3C, left). HMGB1 was also
localized in the nuclei in the majority of cells of islets with
insulitis. However, a large proportion of HMGB1 had
translocated into the cytoplasm in some of the inﬁltrated
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FIG. 1. rHMGB1 is potent to stimulate RAW264.7 cell and NOD dendritic cell activation. A: rHMGB1 stimulated RAW264.7 cells to secret high
levels of TNF-, whereas blockade of HMGB1 by a neutralizing antibody signiﬁcantly inhibited TNF- secretion. Of note, the neutralizing
antibody alone did not show any stimulating effect on RAW264.7 cells, and addition of an unrelated antibody (Ab) failed to block HMGB1-induced
RAW264.7 cell activation, indicating the speciﬁcity of the blocking effect. B: rHMGB1 is potent in stimulating NOD BMDC maturation. When 25
g/ml HMGB1 neutralizing antibody was added into the cultures 1 h before the addition of 20 g/ml rHMGB1, the stimulatory effect of rHMGB1
was almost completely blocked by the neutralizing antibody. Of note, 100 units polymyxin B was also added into the cultures to exclude the effect
of endotoxin. Data shown in the ﬁgure are a representative of four independent experiments performed. C: HMGB1 neutralizing antibody
pretreatment resulted in a reduced NOD BMDC allo-stimulatory capacity. Data shown in the ﬁgure are representative of four independent
experiments carried out in each study group. ***P < 0.001.
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ing HMGB1 active secretion by inﬁltrated immune cells.
To conﬁrm this notion, we double-stained pancreatic islets
for HMGB1 (green) and CD11c (red) and found that some
of these ring-like cells were CD11c
 dendritic cells (Fig.
3C, inset). Taken together, our data suggest that during
autoimmunity, HMGB1 can be either passively released
from damaged -cells or actively secreted by islet inﬁl-
trated immune cells, such as dendritic cells, which could
then enhance autoimmune progression.
Administration of HMGB1 neutralizing antibody pre-
vents diabetes in NOD mice. To determine the implica-
tion of HMGB1 in autoimmune progression, we ﬁrst
performed studies in the early stage of autoimmunity in
8-week-old NOD mice. Forty-one mice were selected for
HMGB1 neutralizing antibody treatment, 17 of which were
housed for monitoring diabetes incidence, and the rest
were used for monitoring insulitis. For controls, 36 mice
were treated with normal IgG, among which 12 were
housed for monitoring diabetes incidence, and 24 were
used for examining insulitis progression. The mice were
treated once a week starting from 8 to 25 weeks of age and
housed up to 35 weeks of age for diabetes onset. Diabetes
incidence was plotted as Kaplan-Meier survival curves. Of
important note, HMGB1 antibody treatment signiﬁcantly
reduced diabetes incidence (Fig. 4A, 47 vs. 75%, P  0.01).
Furthermore, the treatment signiﬁcantly delayed the onset
of diabetes. In average, the age for onset of diabetes in
HMGB1 antibody–treated mice was 28.7 
 3.4 weeks,
whereas the control IgG–treated mice was only 18.4 
 3.1
weeks (P  0.0001).
Next, we checked insulitis severity. Eight mice were
killed for each group at each time point, and a total of
three time points (12, 15, and 18 weeks of age) were
examined. Sections of each pancreas were stained with
hematoxylin-eosin, and insulitis was scored as described
above. As can be seen in Fig. 4B, the extent of insulitis in
HMGB1 antibody–treated mice was signiﬁcantly less se-
vere than the control IgG–treated mice examined at 12
(P  0.0005), 15 (P  0.0006), and 18 (P  0.0001) weeks
old. These data demonstrate that blockade of HMGB1
prevented insulitis progression.
To examine the implication of HMGB1 in the late stage
of autoimmunity, we performed a prevention study in
12-week-old NOD mice, because previous reports suggest
that autoimmune inﬁltration at this stage has already
progressed for at least 5 weeks (31). As above, the mice
were treated with HMGB1 antibody once a week starting
from 12 to 25 weeks of age. Consistently, HMGB1 antibody
treatment signiﬁcantly decreased diabetes incidence (Fig.
4C, 33 vs. 78%, P  0.01). However, there was no signiﬁ-
cant delay for diabetes onset (18.3 
 5.8 vs. 20.9 
 5.5
weeks) as observed in 8-week-old NOD mice. All together,
blockade of HMGB1 signiﬁcantly inhibited insulitis pro-
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FIG. 2. HMGB1 passive release from damaged pancreatic -cells. A: Flow cytometry analysis of NIT-1 cell apoptosis and secondary necrosis
before/after cytokine (10 units/ml IL-1, 100 units/ml TNF-, and 100 units/ml IFN-) stimulation. More than 73% of the cells became apoptotic
after 72 h of cytokine treatment, 79% of which were undergoing secondary necrosis as determined by propidium iodide (PI) and annexin V
staining. B: Western blot analysis of culture supernatants for detection of HMGB1 passive release from damaged NIT-1 cells. NIT-1 cells were
treated with cytokines (IL-1, TNF-, and IFN-), UV light (1 min), and 4 mol/l camptothecin, respectively. Supernatant from each apoptotic
culture was concentrated, and equal volume of elutes was then subjected to Western blot analysis. Lane 1, NIT-1 cell lysates (positive control);
lanes 2–4, culture supernatants of NIT-1 cells treated with combination of cytokines, UV light, and camptothecin, respectively; lanes 5 and 6,
supernatants from necrotic (positive control) and untreated NIT-1 cells (negative control). C: Z-VAD-FMK pretreatment of NIT-1 cells inhibited
cytokine-induced HMGB1 passive release. Z-VAD-FMK (100 mol/l) was added into the cultures 3 h before the addition of cytokines. Lanes 1–3,
NIT-1 cell culture supernatants after cytokine, normal medium (control), and Z-VAD-FMK
cytokine treatment. D: HMGB1 passive release from
damaged primary islet cells. Lanes 1–3, culture supernatants from untreated, cytokine-treated, and necrotic primary islet cells.
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NOD mice.
HMGB1 regulates dendritic cell subpopulation and
functionality. To dissect the mechanisms underlying the
protective effects, we ﬁrst examined the impact on den-
dritic cells. Dendritic cells pooled from pancreatic lymph
nodes (PLNs), inguinal lymph nodes (ILNs), and spleens of
four mice from each study group were used for the study,
and three pools were analyzed. PLN- or ILN-derived den-
dritic cells were analyzed without pre-enrichment to pre-
vent any loss of potentially important cells. We gated
CD11c
 cells and analyzed dendritic cell subpopulations
by CD11c and CD11b expression levels. Interestingly,
HMGB1 antibody treatment signiﬁcantly reduced PLN
CD11c
CD11b
 dendritic cells (Fig. 5A, 14.38 
 1.61 vs.
8.25 
 2.01%, P  0.01). Because CD11c
CD11b
 den-
dritic cells are probably implicated in islet antigen presen-
tation to autoreactive T-cells (32), we then examined their
maturation status by analyzing surface marker expres-
sions. Surprisingly, HMGB1 antibody treatment not only
reduced PLN CD11c
CD11b
 dendritic cells but also
suppressed their maturation, as shown in Fig. 5B. We next
did similar study for PLN and ILN dendritic cell subpopu-
lations in HMGB1 antibody–treated animals. Only very few
CD11c
CD11b
 dendritic cells were present in the ILN;
however, the number and maturation status for ILN
CD11c
CD11b
 dendritic cells were signiﬁcantly lower
than that in the PLN (15.33 
 1.49 vs. 22.09 
 2.22%, P 
0.05; Supplemental Fig. S2). We ﬁnally compared ILN
dendritic cell subpopulations between HMGB1 antibody–
and control IgG–treated animals and failed to detect
signiﬁcant differences in terms of subpopulations and
maturation status (data not shown).
Unlike PLN dendritic cells, HMGB1 antibody treatment
did not show signiﬁcant effect on splenic dendritic cell
maturation (Supplemental Fig. S3). However, the treat-
ment signiﬁcantly inhibited splenic dendritic cell allo-
stimulatory capability (Fig. 6A). To dissect its possible
mechanism, we analyzed splenic dendritic cell subpopula-
tions based on CD11c and CD8 expressions. Interest-
ingly, antibody treatment signiﬁcantly increased the
number of splenic CD11c
CD8
 dendritic cells (23.4 

2.8 vs. 11.6 
 1.0%, P  0.001; Fig. 6B). Because previous
studies suggest that they are probably a subset of toler-
genic dendritic cells (33), the reduced allo-stimulatory
capability of splenic dendritic cells could be caused by the
increase of CD11c
CD8
 dendritic cells.
Blockade of HMGB1 upregulates PLN Tregs. We next
examined the effect of antibody treatment on Treg produc-
tion. CD4
 T-cells pooled from PLNs and spleens were
further analyzed for Foxp3 expressions. It was found that
the proportion of CD4
Foxp3
 T-cells in the PLN CD4

T-cells examined was signiﬁcantly higher in HMGB1 anti-
body–treated mice than the control mice (4.85 
 0.20 vs.
2.89 
 0.15%, P  0.05; Fig. 6C). In contrast, there was no
difference for the splenic Tregs between the two groups of
mice (data not shown).
Blockade of HMGB1 affects CD8
 T-cell subpopula-
tions. To dissect the impact of HMGB1 antibody treat-
ment on T-cell activation, PLN or splenic CD4
 and CD8

T-cells were analyzed by ﬂow cytomety for activation
markers, such as CD69, CD62L
low, and CD44. To our
surprise, antibody treatment showed no effect on the
maturation status for CD4
 or CD8
 T-cells (data not
shown). We then checked CD4
 and CD8
 T-cell subpopu-
lations. Unexpectedly, antibody treatment signiﬁcantly
increased PLN CD8
 T-cells (16 
 1.9 vs. 11.96 
 2.5%,
P  0.05). Next, we examined the proportion of
CD4
IFN-
 (Th1) and CD8
IFN-
 (Tc1) cells. PLN or
splenic CD4 or CD8 T-cells were intracellularly stained for
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FIG. 3. HMGB1 active secretion by NOD dendritic cells and islet inﬁltrated immune cells. A: Cytoplasmic translocation of HMGB1 after
stimulation in NOD dendritic cells. HMGB1 was stained green, and nuclei were stained red. Before stimulation, HMGB1 was exclusively localized
in the nuclei of NOD BMDCs. On 0.5 g/ml LPS stimulation, a large proportion of HMGB1 had translocated into the cytoplasmic vesicles for active
secretion. B: NOD dendritic cells secrete high levels of HMGB1 into the culture medium in a time-dependent manner. HMGB1 was present in the
culture supernatant after8ho fstimulation, with the highest levels observed after 24 h of stimulation. Of note, BMDCs showed similar viability
before and after stimulation as determined by annexin V and propidium iodide (PI) staining, which excluded HMGB1 passive release from
damaged BMDCs. C: HMGB1 active secretion by islet inﬁltrated immune cells. HMGB1 was visualized by DAB (brown). Nuclei were also
counterstained blue by hematoxylin. In a normal islet, HMGB1 was solely localized within the nuclei of islet cells (left). In an islet with severe
insulitis (right), HMGB1 was also exclusively localized in the nuclei in the majority of the cells. However, HMGB1 had translocated into the
cytoplasm in some of the inﬁltrated immune cells (ring-like cells, indicated by arrows), indicating HMGB1 active secretion. Double staining for
HMGB1 (green) and CD11c (red) conﬁrmed that some of these ring-like cells were CD11c
 dendritic cells (inset). (Please see http://dx.doi.org/
10.2337/db07-1499 for a high-quality digital representation of this ﬁgure.)
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cantly higher proportion of PLN CD8
IFN-
 (Tc1) cells
was observed in antibody-treated animals (13.85 
 2.87 vs.
8.75 
 1.32%, P  0.01; Fig. 7). A similar trend was also
observed in the splenic T-cells examined but did not reach
statistical signiﬁcance (17.69 
 2.11 vs. 15.02 
 1.69%). On
the contrary, there was no signiﬁcant difference detected
for the proportion of PLN or splenic CD4
IFN-
 (Th1)
cells between the two groups of mice.
DISCUSSION
Hmgb1 probably originated 500 million years ago before
the split between the animal and plant kingdoms. It is
among the most evolutionarily conserved proteins in the
eukaryotic kingdom and shares 99% amino acid identity
between rodents and humans. Recently, we have demon-
strated a pivotal role for HMGB1 in the initiation and
progression of allograft rejection by acting as an innate
alarmin. Because allograft rejection and type 1 diabetes–
associated autoimmune response share many similar fea-
tures, we reasoned that HMGB1 could also be implicated
in type 1 diabetes pathogenesis. Additionally, the nature of
HMGB1 acting as an innate “danger signal” made it a
perfect molecule for us to dissect the role of innate
immunity in type 1 diabetes development.
We ﬁrst demonstrated the potency for HMGB1 in induc-
ing NOD dendritic cell and macrophage activation, and we
investigated the origin of extracellular HMGB1 during
autoimmunity in NOD mice. HMGB1 passive release from
necrotic cells has been demonstrated in the previous
studies (34). Recent studies also support that HMGB1
passive release is a feature of apoptosis at least in some
cell types and likely occurs during late apoptosis (35,36).
-Cells do not seem to be exceptional in this regard, as
shown in our study. Given that apoptosis and secondary
necrosis may be the dominant form of -cell death during
insulitis course (37), we induced -cell death by cytokines,
UV, and camptothecin and then checked HMGB1 release.
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FIG. 4. Blockade of extracellular HMGB1 prevents insulitis progression and diabetes onset in NOD mice. A: HMGB1 neutralizing antibody (Ab)
treatment prevented diabetes onset in 8-week-old NOD mice. Blockade of HMGB1 in 8-week-old NOD mice not only decreased diabetes incidence
(75 vs. 47%, P < 0.01) but also delayed the onset of diabetes (28.7  3.4 vs. 18.4  3.1 weeks, P < 0.0001). B: A bar graph showing insulitis severity
examined at 12, 15, and 18 weeks after HMGB1 neutralizing antibody treatment (left). A table showing the distribution and parallel comparison
of insulitis score at each time point examined (right). Insulitis scores were estimated in a blinded fashion by two examiners. The differences for
insulitis severity between antibody- and control IgG–treated animals at each time point were analyzed by 
2 test with corrections. HMGB1
antibody treatment signiﬁcantly inhibited insulitis severity at 12-week (P < 0.0005), 15-week (P < 0.0006), and 18-week (P < 0.0001) time
points. C: HMGB1 neutralizing antibody treatment prevented diabetes onset in 12-week-old NOD mice. The mice were treated with either 600 g
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secondary necrosis after cytokine treatment, which re-
sulted in HMGB1 passive release (Fig. 2). We also demon-
strated NOD BMDC and macrophage secretion of HMGB1
after stimulation (Fig. 3A), which resembled the observa-
tions obtained from human dendritic cells. In situ immu-
nostaining further indicated HMGB1 secretion by islet-
inﬁltrated immune cells, such as dendritic cells (Fig. 3C).
These ﬁndings suggest that extracellular HMGB1 in the
pancreatic islets during autoimmunity could originate
from both damaged -cells and inﬁltrated immune cells,
such as dendritic cells.
The presence of HMGB1 in the insulitis lesion suggests
its importance in type 1 diabetes pathogenesis. To address
this question, we ﬁrst treated 8-week-old NOD mice with
an HMGB1 blocking antibody. As expected, blockade of
HMGB1 not only signiﬁcantly prevented insulitis progres-
sion and decreased diabetes incidence but also delayed
the onset of diabetes (Fig. 4). Similar results were also
obtained for the studies in 12-week-old NOD mice. How-
ever, blockade of HMGB1 in 12-week-old NOD mice failed
to delay the onset of diabetes, indicating that it is more
difﬁcult to block autoimmunity once it progressed to the
late stage. However, this phenomenon may also be asso-
ciated with shorter blocking antibody treatment, because
blocking antibody administration did not start before 12
weeks of age and was stopped once the mice reached 25
weeks of age.
Given the critical role of dendritic cells in type 1
diabetes–associated autoimmunity, we ﬁrst checked the
impact for blockade of HMGB1 on dendritic cells, the most
potent APCs known today. It was found that antibody
treatment reduced the number and maturation of
CD11c
CD11b
 dendritic cells in the PLN (Fig. 5A and
B). This observation is consistent with the functionality of
these dendritic cells because they are probably associated
with autoantigen presentation to naı ¨ve T-cells in the PLN
(32). We further noticed higher number and more matured
CD11c
CD11b
 dendritic cells in the PLN than that in the
ILN in HMGB1 antibody-treated animals (Supplemental
Fig. S2), suggesting that they might also be implicated in
autoantigen presentation. Of note, HMGB1 antibody treat-
ment apparently did not have an effect on these dendritic
cells, because both HMGB1 antibody– and control IgG–
treated animals showed similar characteristics for these
dendritic cells. Our studies also suggested a role for
HMGB1 regulation of splenic dendritic cells. After block-
ade of HMGB1, the mice showed a skewed population of
CD11c
CD8a
 dendritic cells (Fig. 6B), which have been
suggested to be responsible for inducing peripheral toler-
ance to tissue-associated antigens (33). Consistently,
splenic dendritic cells originated from antibody-treated
mice had a decreased allo-stimulatory capability (Fig. 6A).
We also noticed that HMGB1 antibody treatment re-
sulted in increased CD4
Foxp3
 Tregs in the PLN (Fig.
6C). The basis for this observation is not clear from our
studies. Previous studies in other model systems have
shown that a subset of dendritic cells can induce Treg
production (38–40). Therefore, blockade of HMGB1 may
modulate dendritic cells to an appropriate maturation
state that can induce Treg development. Also, blockade of
HMGB1 may have an effect on Treg migration, which leads
to Treg accumulation in the PLN.
Of note, blockade of HGMB1 did not show an observ-
able effect on T-cell activation. However, blockade of
HMGB1 unexpectedly increased the number of total CD8

T-cells in the PLN. Consistent with this observation, the
proportion of CD8
IFN-
 cells (Tc1) in the PLN and
spleen was higher in antibody-treated mice compared with
the control mice (Fig. 7). The exact mechanism responsi-
ble for this observation remains unclear. Based on the fact
that HMGB1 antibody treatment signiﬁcantly inhibited
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FIG. 5. Blockade of extracellular HMGB1 regulates PLN dendritic cell subpopulation and maturation. A: HMGB1 antibody (Ab) treatment reduced
the number of PLN CD11c
CD11b
 dendritic cells. PLN cells pooled from four mice were gated for CD11c
 cells and then analyzed for
subpopulations based on CD11c and CD11b expression levels. A representative of ﬂow cytometry data are shown in the top. The data are
presented in the table (bottom) as means  SD of three pools studied in each group. B: A bar graph showing the effect of HMGB1 antibody
treatment on PLN CD11c
CD11b
 dendritic cell maturation. The treatment signiﬁcantly inhibited I-Ad and CD54 expression compared with the
control IgG–treated mice. The data shown here are means  SD of three pools studied. *P < 0.01.
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islet-inﬁltrated immune cells (Fig. 4B), this phenomenon
could be associated with retarded migration of activated
autoreactive T-cells from PLN into the pancreatic islets
after blockade of HMGB1. In fact, a similar result was
observed in the experimental autoimmune encephalomy-
elitis model. Yan et al. (41) noticed that after blockade of
receptors for advanced glycation end products, a co-
receptor for HMGB1 prevented the entry of encephalito-
genic T-cells into the central nervous system. Taken
together, these results indicate that HMGB1 could affect
the migration of activated autoreactive T-cells into the
target organ.
In summary, we demonstrated strong evidence indicat-
ing the involvement of HMGB1 in type 1 diabetes patho-
genesis. Blockade of extracellular HMGB1 signiﬁcantly
inhibited insulitis progression and diabetes development
in NOD mice. The mechanisms underlying this protective
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FIG. 6. Blockade of extracellular HMGB1 regulates splenic den-
dritic cell function and PLN Tregs. A: Splenic dendritic cells
originated from antibody (Ab)-treated mice showed a reduced
allo-stimulatory capacity. There was no surface marker expression
difference observed between the experimental and control animals,
but the allo-stimulatory capability was signiﬁcantly lower in anti-
body-treated mice. **P < 0.001. B: HMGB1 antibody treatment
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and the regulation of autoimmune response.
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